Clinical and laboratory features of patients with Candida auris cultures, compared to other Candida, at a South African Hospital

Amirah Parak1, Sarah Lynn Stacey2, Vindana Chibabhai3,4

1 Department of Internal Medicine, University of the Witwatersrand Johannesburg, South Africa
2 Division of Infectious Diseases, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa
3 Microbiology Laboratory, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa
4 Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, South Africa

Abstract

Introduction: Multidrug resistant Candida auris is an emerging threat worldwide. It has been identified in Africa, however, there is minimal data available comparing C. auris to other Candida species in Africa.

Methodology: Retrospective, case control study at a tertiary South African Hospital. Clinical and laboratory features of patients with positive C. auris clinical cultures from 1 January 2015 to 31 August 2018 were compared to patients who cultured C. albicans and C. glabrata.

Results: Forty-five clinical cases with C. auris cultures were identified. The median age was 32 years (IQR = 26 -46). The median duration of hospital stay was 64 days (IQR = 39-88) and median time from admission to diagnosis 35 days (IQR = 21-53). Indwelling devices and previous antibiotic exposure were found to be significant risk factors. All C. auris isolates were susceptible to amphotericin B and micafungin. Patients treated with amphotericin B alone, had a higher mortality (73.33%, n = 11/15) than patients treated with an echinocandin (54.55%, n = 6/11), however this was not statistically significant. All C. auris isolates were healthcare associated with 80% (n = 36/45) acquired in ICU. The 30-day all-cause in-patient mortality was 42% (n = 19/45) for C. auris, 36% (n = 16/45) for C. albicans and 53% (n = 24/45) for C. glabrata.

Conclusions: C. auris is an emerging multi drug resistant threat in South Africa. Improved access to echinocandins and improvement of infection prevention and control strategies are imperative to prevent further morbidity and mortality due to this pathogen.

Key words: Candida auris; candidemia; drug resistant Candida.

J Infect Dev Ctries 2022; 16(1):213-221. doi:10.3855/jidc.14917

(Received 16 February 2021 – Accepted 09 June 2021)

Copyright © 2022 Parak et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Candida species are commensals of the skin and mucosal surfaces in healthy individuals. However, in immunocompromised patients, these fungi can cause invasive disease [1,2]. Candida species are a common cause of health care associated bloodstream infections [3,4]. In the past, Candida albicans was the predominant cause of infection, however, there has been a recent shift to non-albicans Candida species (NAC) causing disease [5,6]. Candida auris is an emerging species causing healthcare associated infections (HAI). First identified in 2009, from the external ear canal of a patient in Japan [7], it has since been identified in several countries globally, including South Africa [8-18].

Previously, the commonest Candida species, causing disease in South Africa, was C. albicans followed by C. glabrata [19-21]. However, 2016 National institute of communicable diseases (NICD) surveillance, found that C. parapsilosis, was the commonest followed by C. albicans and C. auris ranked fourth [22]. Eleven percent of candidemia in South Africa was due to C. auris in 2016-2017; 94.2% of cases were in Gauteng province [23,24].

Length of hospitalisation prior to infection differs between species. The average number of days between hospitalization and C. auris infection was 24 days [14] and 27.5 days [15], in 2 studies, and 3.5 [25] days for C. glabrata. In intensive care unit (ICU) patients, the median length of stay prior to diagnosis was 25 days for C. auris, 14 days for C. albicans and 16.5 days for C. glabrata [12].

Detection of Beta-D-glucan (BDG) is found to be a useful adjunct for the diagnosis of deep-seated Candida infections due to C. albicans and C. glabrata. A South African study showed 71% sensitivity of BDG in C. auris candidemia [26].
Known risk factors for C. auris are urinary catheters, central venous catheters (CVC), underlying malignancy, chronic kidney disease, neutropenia, total parenteral nutrition (TPN), increased length of stay, mechanical ventilation, immunosuppressive states and prior broad spectrum antibiotic use [10-12,14,15,23,27]. Mortality ranges from 28-50% in published studies [10,12,14,15].

There are currently no established clinical breakpoints for C. auris, but the CDC has provided tentative breakpoints [18]. C. auris is the first Candida species to be classified as multidrug resistant. Studies from multiple countries have demonstrated resistance to fluconazole [9-12,14,15,28]. The CDC, Public Health England and South African guidelines recommend echinocandins as first line treatment. However, for eye, urinary tract, central nervous system infections and in infants under two months old, amphotericin B is recommended [18,29,30]. The South African public health sector has minimal access to echinocandins and negligible access to liposomal amphotericin B.

**Aim of the study**

Little information is available on the clinical aspects of C. auris infection and colonisation compared to other Candida species where virulence and antifungal resistance differs. C. auris has been found to be both equally virulent as C. albicans [31] and demonstrates high minimum inhibitory concentrations (MICs) to azoles, similar to C. glabrata [28]. The aim of this study was to determine whether clinical features, risk factors and outcomes of patients who cultured C. auris differed from those who cultured C. albicans and C. glabrata.

**Methodology**

**Study population and study design**

This retrospective, case control study was conducted at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), a tertiary public hospital in the Gauteng province of South Africa. A deduplicated list of C. auris isolates, during the period 1 January 2015 to 31 August 2018, was obtained from the National Health Laboratory Service (NHLS). A case of C. auris was defined as a positive culture, from any site, during the study period. The first positive specimen was included, and duplicates (cultured within the same admission) were counted as a single case. These cases were matched against patients with C. glabrata and C. albicans cultures. Cases were matched based on ward, age and site of culture. Patients with the closest age (within a 10-year range) were included.

**Microbiological methods**

Routine culture medium (5% sheep blood agar, chocolate agar and sabouraud dextrose agar) was used to culture C. auris. The Vitek 2® (bioMérieux, Marcy-l’Étoile, France) system was used for identification and susceptibility testing of yeasts. The CDC tentative breakpoints were used to interpret susceptibility results for C. auris and the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing guidelines were used for C. albicans and C. glabrata [18,32]. The Fungitell® assay (Associates of Cape Cod, Massachusetts, United States of America) was used for BDG testing and interpreted according to the manufacturer’s recommendations. Microscopy of samples using standard microbiological methods were used for bacterial culture. The samples were plated out onto solid agar (including 5% blood, chocolate and MacConkey agar where appropriate). Additional media were dependent on the sample type. Identification of the bacteria was performed using Vitek® mass spectrometry matrix assisted laser desorption ionization- time of flight mass spectrometry (bioMérieux, Marcy-l’Étoile, France) or Vitek® 2 (bioMérieux, Marcy-l’Étoile, France) automated microbial identification and antibiotic susceptibility testing.

**Data collection**

Inpatient files were retrieved from archives. Information on demographics, clinical features, laboratory investigations within 24 hours of collection of the positive culture, risk factors, treatment and outcomes were entered into an anonymized Microsoft Excel spreadsheet.

**Statistical analysis**

Standard analyses were performed for the data. Microsoft Excel was used for basic analysis. Categorical variables were reported as frequencies and percentages and continuous variables were reported as median and interquartile range (IQR). Statistica™ (version 14) software was then used for further analysis. Continuous variables were analysed using the Mann-Whitney U Test and categorical variables were analysed using the Chi-Square Test. Confidence interval of 95% were used and p values < 0.05 were considered statistically significant.

**Study definitions**

- Healthcare associated infection: a positive Candida culture, more than 48 hours after admission,
associated with clinical or laboratory features of infection.

- ICU acquired candidiasis: Culture of Candida species obtained 48 hours after ICU admission or within 48 hours of discharge from ICU.
- Antifungal exposure: empiric or prophylactic therapy with an antifungal agent up to 30 days prior to the diagnosis of candidiasis.
- Outcome: determined 30 days after the diagnosis of candidiasis.
- Thirty day all cause in-patient mortality: number of patients who died whilst still in-patients, within 30 days of onset of candidiasis, regardless of cause of death.
- Temperature spikes: an intermittent sharp rise in body temperature, with resolution to baseline. These intermittent increases in temperature lasted between 24 and 48 hours.
- Sepsis: life threatening organ dysfunction caused by dysregulated host response to infection [33].
- Septic shock: sepsis with circulatory and cellular/metabolic dysfunction [33].
- Hypotension: systolic blood pressure < 90mmhg and diastolic blood pressure < 60mmhg.

**Ethical considerations**

Permission to perform the study was granted by the Human Research Ethics Committee of the University of the Witwatersrand (certificate number: M180307).

### Results

From 1 January 2015 to 31 August 2018, *C. auris* isolates were identified from clinical specimens of 45 patients, *C. albicans* from 1,959 specimens and *C. glabrata* from 185 specimens. Patient demographics are summarized in Table 1 and site of culture in Table 2. Isolates from more than one site were counted separately, and recorded in Table 2, resulting in higher numbers in Table 2. All *C. auris* infections were HAI, whereas 80% (n = 36/45) of *C. albicans* and *C. glabrata* were HAI. Of the 45 *C. auris* cases, 5 were paediatric (age < 12), and ages ranged from 1 month to 73 years.

### Clinical features

Clinical information was available for 41 patients with *C. auris* and all 45 cases of *C. albicans* and *C. glabrata*. Table 3 summarizes clinical features. Fever was more common in the *C. auris* group than in both the other groups (*p* < 0.001). Twelve *C. auris* patients had fever and hypotension. Of these patients, 50% (n = 6/12) had a positive bacterial culture.

### Laboratory features

*C. auris* was cultured from non-sterile sites in 26.66% of cases (n = 12/45). However, 41.67% (n = 5/12) patients concurrently cultured *C. auris* from a sterile site. Fifteen patients cultured *C. auris* from a catheter tip. Of these patients, 40% (n = 6/15) also had positive blood cultures, confirming a catheter-related candidemia.
Table 3. Clinical Features.

|          | C. auris | C. albicans | C. glabrata |
|----------|----------|-------------|-------------|
| Hypotension, n (%) | N = 41 | 12 (29.27) | N = 45 | 10 (22.22) | N = 45 | 15 (33.33) |
| Sepsis, n (%) | N = 41 | 16 (39.02) | N = 45 | 14 (31.11) | N = 45 | 17 (39.53) |
| Fever, n (%) | N = 41 | 28 (68.29) | N = 45 | 14 (31.11) | N = 45 | 15 (33.33) |
| Altered mental state, n (%) | N = 41 | 21 (57.14) | N = 45 | 7 (15.62) | N = 45 | 1 (6.67) |
| Temperature spikes, n (%) | N = 28 | 21 (75) | N = 14 | 7 (50) | N = 15 | 1 (6.67) |
| Other immunosuppressant | N = 41 | 29 (70.73) | N = 45 | 22 (48.89) | N = 45 | 224 (53.33) |
| Septic shock, n (%) | N = 41 | 11 (26.83) | N = 45 | 9 (20) | N = 45 | 12 (26.67) |

* statistical significance.

Table 4. Laboratory results.

|          | C. auris | C. albicans | C. glabrata |
|----------|----------|-------------|-------------|
| Haemoglobin [g/dL], mean (IQR) | N = 43 | 8.3 (7.9-9.6) | N = 42 | 9.20 (7.95-11.25) | N = 45 | 9.20 (9.1-11.3) |
| White cell count [10^9/L], median (IQR) | N = 43 | 10.69 (7.69-18.82) | N = 42 | 13.85 (9-21.21) | N = 45 | 11.84 (7.13-18.45) |
| Platelet count [10^9/L], median (IQR) | N = 43 | 260 (161-351) | N = 42 | 232 (179.25-342) | N = 44 | 209 (124.5-341.25) |
| Albumin [g/L], median (IQR) | N = 36 | 22.50 (20.26-25.26) | N = 31 | 26 (22.5-28.5) | N = 37 | 23 (19-26) |
| Creatinine [µmol/L], median (IQR) | N = 44 | 83.5 (53.5-269) | N = 42 | 76.50 (52-187.75) | N = 45 | 93.5 (102.5-187.75) |
| CRP [mg/L], median (IQR) | N = 31 | 75 (48-214) | N = 34 | 178 (118-229.5) | N = 39 | 180 (102.5-246.5) |
| CRP [mg/L] without cultured bacterial organisms, median (IQR) | N = 19 | 61.50 (40-117) | N = 17 | 159 (118-220) | N = 21 | 160 (74-229) |
| Pro calcitonin [µg/L], median (IQR) | N = 33 | 3.38 (0.62-39.03) | N = 23 | 2.77 (1.13-6.36) | N = 29 | 7.89 (2.14-36.94) |
| PCT [µg/L] without cultured bacterial organisms, median (IQR) | N = 16 | 1.45 (0.44-5.64) | N = 7 | 2.43 (0.57-6.92) | N = 14 | 4.41 (0.98-13.54) |
| Beta D Glucan [pg/mL], median (IQR) | N = 15 | 306 (185-523) | N = 14 | 298 (119.25-493.75) | N = 17 | 278 (60-843) |

* statistical significance.

Table 5. Risk factors for Candida infections.

|          | C. auris | C. albicans | C. glabrata |
|----------|----------|-------------|-------------|
| N | % (n) | N | % (n) | N | % (n) |
| Previous hospitalization | 45 | 8.89 (4) | 45 | 13.33 (6) | 45 | 26.67 (12) |
| Median number of days from discharge | 8 (IQR 6.25-9.75) | 13 (IQR 2.25-19.25) | 12 (IQR 8-19.5) |
| Number of days from admission to positive result, median (IQR) | 35 (21-53) | 8 (3-19) | 8 (2-18) |

* p values significant.
Four of the other nine patients, did not have paired blood cultures done, and five had blood cultures that were negative for *C. auris*. Nine patients cultured *C. auris* from urine samples, of these patients, eight had an indwelling urinary catheter. Table 4 summarizes the results of laboratory investigations within 24 hours of culture collection.

Bacteria were cultured concurrently in 46.67% (n = 21/45) of patients with *C. auris*, 51.11% (n = 23/45) of patients with *C. albicans* and 44.44% (n = 20/45) of patients with *C. glabrata*. Common organisms cultured are shown in Figure 1.

Where candidaemia was suspected, 33.33% (n = 15/45) of patients with *C. auris*, 31.11% (n = 14/45) of *C. albicans* and 37.78% (n = 17/45) of *C. glabrata* patients had a BDG test performed on blood. The overall sensitivity of BDG was 86.67% for *C. auris*, 92.31% for *C. albicans* and 64.71% for *C. glabrata*.

The sensitivity of BDG for isolates cultured from sterile sites only, was 84.62% for *C. auris*, 100% for *C. albicans* and 81.82% for *C. glabrata*.

Forty-one patients had susceptibility results available for *C. auris*, but only 25 patients had MIC data available. All 25 isolates were resistant to fluconazole with high MICs of > 256 µg/mL; MIC\(_{50}\) and MIC\(_{90}\) for voriconazole were 1 µg/mL and 32 µg/mL respectively. All isolates were susceptible to amphotericin B and micafungin with an MIC\(_{50}\) of 0.25 µg/mL and MIC\(_{90}\) of 1 µg/mL for amphotericin B and MIC\(_{50}\) of 0.06 µg/mL and MIC\(_{90}\) of 0.12 µg/mL for micafungin. There were 29 isolates of *C. albicans* with MIC results available. All isolates were susceptible to azoles with a MIC\(_{50}\) of 0.12 µg/mL and MIC\(_{90}\) of 0.25 µg/mL for fluconazole and MIC\(_{50}\) and MIC\(_{90}\) both 0.03 µg/mL for voriconazole. MIC results were available for 26 *C. glabrata* isolates. The MIC\(_{50}\) was 32 µg/mL and MIC\(_{90}\) was 64 µg/mL for fluconazole and 46.15% (n = 12/26) isolates were susceptible to dose dependant fluconazole. The voriconazole MIC\(_{50}\) was 0.25 µg/mL and MIC\(_{90}\) 1 µg/mL. All *C. glabrata* isolates were susceptible to amphotericin B but MICs were not available.

**Risk factors**

There was an association between indwelling devices and *C. auris* culture, compared to patients with *C. albicans* and *C. glabrata*. Of the *C. auris* patients with indwelling devices, 18 patients had both haemodialysis catheter and central venous lines. Table 5 details the comparative risk factors between the 3 species.

Antimicrobial exposure data is available for 43 patients. In the 30 days prior to infection or colonisation with *C. auris*, 97.67% (n = 42/43) patients received antimicrobials. The percentage of patients that received specific antimicrobials are listed in Figure 2. Prior antimicrobial exposure was significantly associated with *C. auris* infection (p < 0.001). Thirty-five patients, with *C. auris*, underwent a surgical procedure; 57.14% (n = 20/35) had abdominal surgery, 25.71% (n = 9/35) had thoracotomies and 14.29% (n = 5/35) had craniotomies. Repeat/relook surgery was performed in 65.71% (n = 23/35) of surgical patients and 82.61% (n = 19/23) of these patients had multiple (≥ 2) secondary surgical procedures. Surgical procedures were undertaken in 42.86% (n = 15/35) of patients for traumatic injuries, ranging from gunshot wounds to blunt force trauma. Multiple surgery was a significant risk factor in both comparison groups (p = 0.003 for *C. auris* vs. *C. albicans* and p = 0.03 *C. auris* vs. *C.
glabrata). Of the patients that presented with community acquired C. albicans and C. glabrata, 66.67% (n = 6/9) of the C. glabrata and 55.56% (n = 5/9) of the C. albicans patients had perforated gastrointestinal organs with intra-abdominal sepsis.

The majority of C. auris cases, 80% (n = 36/45), were cultured during the course of ICU admission, compared to 46.67% (n = 21/45) C. albicans and 37.78% (n = 17/45) of C. glabrata cases.

**Treatment**

Treatment data for 43 patients with C. auris was available. Fifteen patients (34.89%) were not treated. Seven of these patients died within 1-12 days of the positive culture result. Three of these patients had candidemia, two cultured C. auris from CVC tips and two from urine.

Treatment was initiated in 65.12% (n = 28/43) of patients. The median number of days from culture identification of C. auris to initiation of treatment was 5 days (IQR = 3.25-7), in both the micafungin and amphotericin B groups. Micafungin was administered to 39.29% (n = 11/28) of patients, of which 54.55% (n = 6/11) died. Three of the 6 patients who died were initially treated with amphotericin B, then switched to micafungin. Amphotericin B was initiated in 63.64% (n = 18/28) of patients. Of the 15 patients treated with amphotericin B alone, 73.33% (n = 11/15) died. The remaining two patients were treated with fluconazole.

Treatment duration was available for only seven patients who survived. The average number of days of treatment was 16.7 days (IQR = 14-17.5). Of the treated patients who died, 11 died while still receiving treatment, with duration of therapy ranging from 1-12 days of treatment. The difference in mortality rate for C. auris patients, treated with micafungin versus amphotericin B, was not statistically significant (p = 0.32).

In the C. albicans group, 40% (n = 18/45) of patients received treatment, of which 88.89% (n = 16/18) were initiated on fluconazole. Two patients were initiated on amphotericin B then de-escalated to fluconazole. The median time from positive result to treatment initiation was 5 days (IQR = 2-5).

In the C. glabrata group, 48.89% (n = 22/45) of patients received treatment. Fluconazole was initiated in 43.64% (n = 10/22) of patients. Susceptibility data was only available for six of these patients, of which four were resistant to fluconazole, and 20% (n = 2/10) were subsequently escalated to amphotericin B. Amphotericin B was administered to 63.64% (n=14/22) of patients and one patient was switched to micafungin. The median time from positive result to commencement of treatment was four days (IQR = 0.25-6). Of the patients treated with fluconazole, 70% (n = 7/10) died and 71.43% (n = 10/14) of patients treated with amphotericin B died.

**Outcomes**

From the 28 C. auris patients that were treated, 39.29% (n = 11/28) patients died prior to completion of treatment, 53.57% (n = 15/28) were successfully treated and 2 patients had incomplete outcome data.

The median number of days from diagnosis of C. auris to death was 13 days (IQR = 6.5-34). The median number of days from diagnosis to death for C. albicans was 9 days (IQR = 3-18) and for C. glabrata 7 days (IQR = 1-14). Of the C. auris patients that died, 94.74% (n = 18/19) had ICU acquired infections. The 30-day all-cause in-patient mortality overall is shown in Figure 3. For patients with candidemia, the 30-day all-cause mortality was 57.70% (n = 15/26) in the C. auris group, 58.33% (n = 7/12) for C. albicans and 77.27% (n = 17/22) for C. glabrata. All C. auris cases, 80% (n = 36/45) of C. albicans and 80% (n = 36/45) of C. glabrata cases were hospital acquired.

Of the 26 patients with C. auris candidemia, 76.92% (n = 20/26) were treated, 60% (n = 12/20) of these patients died within 30 days. Of the 19.23% (n = 5/26) untreated patients, 60% (n = 3/5) of patients died. The treatment information of one patient was not available. C. auris candidemia was ICU acquired in 80.77% (n = 21/26) of cases. Of these cases, 66.67% (n = 14/21) died within 30 days.

**Discussion**

This study demonstrates that C. auris is indeed an emerging threat in South Africa and is associated with
ICU admissions. In this cohort, mortality was 42%, which falls within the range of 28-50% in published studies [10,12,14,15].

In this study, more males than females were infected with C. auris. This is possibly due to the nature of the underlying pathology, as 33.33% (n = 15/45) of patients were admitted for traumatic injuries requiring surgery, and only one of these patients were female.

A longer length of hospital stay, as well as longer duration from admission to diagnosis was statistically significant in the C. auris group compared to the other two Candida species. The median time from admission to diagnosis of C. auris was 35 days, which was approximately a week longer than in previous studies [14,15]. Median time from admission to diagnosis of C. glabrata, in a previous study, was 3.5 days, compared to 8 days in this study [25].

Patients were not routinely screened for C. auris colonization on admission. The total number of infected patients that were colonized is unknown. C. auris was predominantly (84.44%, n=38/45) cultured from sterile sites which suggests infection rather than colonization. However, it is possible that candidaemia was missed in patients with negative blood cultures as a result of poor sensitivity of blood cultures for Candida spp. In addition, biochemical features suggest that, at the time of diagnosis, patients were systemically ill with low median albumin and haemoglobin in all 3 groups.

No specific clinical features were found to be associated with C. auris infection. Many patients had a fever, but it is difficult to conclude if the fever was due to C. auris alone, or due to the concurrent bacterial infection.

The CRP and PCT in patients that cultured C. auris alone (median CRP 61.50 mg/L and PCT 1.45 µg/L) were lower than in patients that cultured bacteria as well (median CRP 75 mg/L and PCT 3.38 µg/L). A study comparing bacterial and fungal infections, found a PCT > 5.5 µg/L was associated with bacterial infections and not candidaemia [34]. Median PCT in candidaemia was found to be 0.7 µg/L [35], 0.99 µg/L [36] and 0.5 µg/L [37] in 3 different studies. A raised CRP with a low positive PCT may suggest an isolated fungal infection [37,38]. BDG sensitivity was 86.67% for C. auris. BDG can be used as an adjunct to other diagnostic assays for fungal infections but cannot be used to distinguish between different Candida species [26].

The MIC for amphotericin B in our study was lower than other published studies [12,14,15] but the MIC for micafungin is similar to previous studies [10-12,14]. There was no resistance to amphotericin B or micafungin, but all organisms were resistant to fluconazole. Despite having a low MIC, patients treated with amphotericin B alone, had a higher mortality (73.33%, n = 11/15) than patients treated with an echinocandin (54.55%, n = 6/11). The causes of mortality in the amphotericin B group were not assessed. We can therefore not conclude, from this study, if the increased mortality was due to poor treatment response, drug toxicity or non C. auris related factors.

It is evident that all indwelling devices predispose patients to C. auris infection. However, the duration of exposure to the indwelling device was not assessed. HIV co-infection was not a significant risk factor and C. auris infection occurred in patients with a high CD4 count. Immunosuppressant use, specifically glucocorticoids, was documented in many patients but was not a statistically significant risk factor for the development of C. auris.

Surgical procedures and antimicrobial exposure are risk factors for C. auris infections [10,11,15,25]. In this study, the number of repeat surgeries was significantly associated with C. auris infection, as was the exposure to antimicrobials.

In this study, 80% of C. auris infections were acquired in ICU. Since C. albicans and C. glabrata cases were matched for ward-type with C. auris cases, the high number of these organisms found in ICU is not a true reflection of the Candida distribution throughout the hospital.

The findings of this study are limited due to incomplete clinical data, and small sample size. In addition, isolates that were not identified by the microbiology laboratory, and released as ‘yeast not Candida albicans’ or ‘Candida species’ may have been missed C. auris isolates. Matching of C. albicans and C. glabrata patients was performed manually and may have resulted in some bias. In addition, cases should have been matched for site of infection first, with a particular focus on bloodstream infections. A control group with no candidaemia was not included to compare clinical findings and risk factors, thus the data provided here may be partial. The incidence of candidaemia at this hospital was not calculated. Information regarding inter hospital transfer or recent admission to other hospitals was not collected. Appropriateness of antifungal dosing was not assessed. No data was collected to evaluate source control. There are multiple confounding factors affecting the mortality rate, especially severity of the underlying illness, which have not been addressed in this study.
Conclusions

At CMJAH, C. auris is a healthcare associated pathogen specifically associated with ICU admission, increased length of hospitalisation, broad spectrum antimicrobials and indwelling devices. Diagnosis in this setting may be assisted by non-culture based assays such as the BDG in combination with inflammatory markers such as the CRP and PCT, but may only be valuable in cases where no concomitant bacterial infection is present.

Considering the high mortality rate associated with this MDR pathogen, it is imperative that intensive infection control measures are implemented to prevent horizontal transmission of C. auris. Equally important is a commitment to robust antimicrobial stewardship in order to curb resistance and emergence of further multidrug resistant pathogens.

Authors’ contributions

Amirah Parak was the principal investigator and primary author of the protocol and final manuscript. Sarah Stacey and Vindana Chibabhai conceptualised the study and assisted with study design, editing and approving of the final manuscript.

References

1. Kühbacher A, Burger-Kentscher A, Rupp S (2017) Interaction of Candida species with the skin. Microorganisms 5: 32.
2. Underhill DM, Iliev DI (2014) The mycobiota: interactions between commensal fungi and the host immune system. Nat Rev Immunol 14: 405–416.
3. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollob L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK (2014) Multistate point-prevalence survey of health care–associated infections. N Engl J Med 370: 1198-1208.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323-2329.
5. Deonukkhar SC, Saini S, Mathew S (2014) Non-albicans Candida Infection: An emerging threat. Interdiscip Perspect Infect Dis: 2014: 615958.
6. Lamoth F, Lockhart SR, Berkow EL, Calandra T (2018) Invasive candidiasis. J Antimicrob Chemother 73: i4–i13.
7. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H (2009) Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 53: 41-44.
8. Emara M, Ahmed S, Khan Z, Joseph L, Al-Obeid J, Purohit P, Bafna R (2015) Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis 21: 1091-1092.
9. Magobo RE, Corcoran C, Seetharam S, Govender NP (2014) Candida auris– associated candidemia, South Africa. Emerg Infect Dis 20: 1250-251.
10. Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, Jain S, Kathuria S, Randhawa HS, Hagen F, Meis JF (2013) New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 19: 1670-1673.
11. Chowdhary A, Kumar VA, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF (2014) Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33: 919-926.
12. Rudramurthy SM, Chakrabarti A, Paul RA, Paul RA, Sood P, Kaur H, Capoor MR, Kindo AJ, Marak RSK, Arora A, Sardana R, Das S, Chhina D, Patel A, Xess I, Tarai B, Singh P, Ghosh A (2017) Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother 72: 1794-1801.
13. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Callfe DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moutlon-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Evintseva AP, Chiller TM (2016) Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus, United States, May 2013–August 2016. Am J Transplant 17: 296-299.
14. Calvo B, Molo ASA, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, Meis JF, Colombo AL (2016) First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect 73: 369-374.
15. Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martinez HP, Rodríguez GI, Álvarez-Moreno CA, Rodriguez JY (2017) Invasive Infections with Multidrug-Resistant yeast Candida auris, Colombia. Emerg Infect Dis 23: 162-164.
16. Shenlenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhry A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC (2016) First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5: 35.
17. Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T (2017) Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis 23: 195-203.
18. Centre for Disease Control and Prevention (CDC) (2019) General Information about Candida auris. Available: https://www.cdc.gov/fungal/candida-auris/candida-auris-qanda.html. Accessed: 1 February 2019.
19. Menge P, Okeleeye BI, Vasaikar SD, Apalata T (2017) Species distribution and antifungal susceptibility patterns of Candida isolates from a public tertiary teaching hospital in the Eastern Cape Province, South Africa. Braz J Med Biol Res 50: e5797.
20. Kreusch A, Karstaedt AS (2013) Candidemia among adults in Soweto, South Africa, 1990-2007. Int J Infect Dis 17: e621-e623.
21. Pfaller MA, Diekema DJ (2004) Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10: 11-23.
22. National Institute of Communicable diseases (NICD) (2017) GERMS-SA Annual Report 2017. Available: http://www.nicd.ac.za/index.php/publications/germs-annualreports. Accessed: 01 February 2019.
23. Van Schalkwyk E, Shuping L, Ismail H, Thomas J, Govender NP (2017) Independent risk factors associated with Candida auris candidemia South Africa – an analysis of national surveillance data, 2016-2017. 7th Conference of the Federation
of Infectious Disease Societies of Southern Africa (FIDSSA); Cape Town, South Africa. 40.

24. Govender NP, Magobo RE, Mpembe R, Mhlanga M, Matlapeng P, Corcoran C, Govind C, Lowman W, Senekal M, Thomas J (2018) *Candida auris* in South Africa, 2012–2016. Emerg Infect Dis 24: 2036-2040.

25. Parmeland L, Gazon M, Guerin C, Argaud L, Lehot J, Bastien O, Allaouchiche B, Michallet P, Picot S, Bienvenu AL (2013) *Candida albicans* and non-*Candida albicans* fungemia in an institutional hospital during a decade. Med Mycol 51: 33–37.

26. Chibabhai C, Fadana V, Bosman N, Nana T (2019) Comparative sensitivity of 1,3 beta-D-glucan for common causes of candidemia in South Africa. Mycoses 62: 1023-1028.

27. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladia M for the Israeli Candidemia Study Group (2012) Antibiotic exposure as a risk factor for fluconazole-resistant *Candida* bloodstream infection. Antimicrob Agents Chemother 56: 2518–2523.

28. John Osei Sekyere (2018) *Candida auris*: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen 7: e00578.

29. Govender N.P, Avenani T, Brink A, Chibabhai V, Cleghorn J, Du Toit B, Govind C, Lewis E, Lowman W, Mahlangu H, Maslo C, Messina A, Mer M, Pieton K, Seetharam S, Sriruttan C, Swart K, Van Schalkwyk E (2019) Federation of infectious diseases societies of Southern Africa guideline: recommendations for the detection, management and prevention of healthcare-associated *Candida auris* colonisation and disease in South Africa. S Afr J Infect Dis 34: a163.

30. Gov.UK (2016) Guidance for the laboratory investigation, management and infection prevention and control for cases of *Candida auris*. Available: https://www.gov.uk/government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control. Accessed: 01 February 2019.

31. Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD, Rautenmaa-Richardson R (2017) Biofilm-forming capability of highly virulent, multidrug-resistant *Candida auris*. Emerg Infect Dis 23: 328-331.

32. Clinical and Laboratory Standards Institute (CLSI) (2017) Performance Standards for Antifungal Susceptibility Testing of Yeasts. CLSI supplement M60-Ed1. (ISBN 1-56238-829-0)

33. Rhodes A, Evans L, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerger B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche J-D, Coopersmith C, De Backer JP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. Intensive Care Med 43: 304–377.

34. Charles PE, Dalle F, Aho S, Quenot JP, Doise JM, Aube H, Olsson NO, Blettery B (2006) Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 32: 1577-1583.

35. Martini A, Gottin L, Menestrina N (2010) Procalcitonin levels in surgical patients at risk of candidemia. J Infect 60: 425-430.

36. Cortegiani A, Russotto V, Montalto F, Foresta G, Accurso G, Palmieri C, Raineri SM, Giarratano SM (2014) Procalcitonin as a marker of *Candida* species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol 14: 9.

37. Leli C, Ferranti M, Moretti A, Al Dhabah ZS, Cenci E, Mencacci A (2015) Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections. Dis Markers 2015: 701480.

38. Raineri SM, Cortegiani A, Vitale F, Iozzo P, Giarratano A (2017) Procalcitonin for the diagnosis of invasive candidiasis: what is the evidence? J Intensive Care 5: 58.

**Corresponding author**
Dr Amirah Parak, MD
Department of Internal Medicine, University of the Witwatersrand Johannesburg, Helen Joseph Hospital, 1 Perth Road, Rossmore, 2006, Johannesburg, South Africa
Phone: +27 114891011
Email: amirahparak@gmail.com

**Conflict of interests:** No conflict of interests is declared.